Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-Avibactam vs Best Available Therapy for Resistant Gram-Negative Infections
NCT01644643Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2013
- Primary completion
- Sep 2014
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 18
01
Overview
A Phase 3 trial of ceftazidime + avibactam in complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI), sponsored by Pfizer. Started Jan 2013; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT01644643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01644643.